Skip to main content
Premium Trial:

Request an Annual Quote

The Truth About Muth

Premium

Talk about ambitious. For David Muth, Structural Bioinformatics’ freshly recruited president and COO whose charter is to steer the tools company toward discovery, a single MBA degree was simply not enough.

The first, in finance from Pace University in 1978, landed him an auditing job at Johnson & Johnson’s corporate headquarters in New Brunswick, NJ. “But it doesn’t take more than a nanosecond to figure out that J&J is a sales-and-marketing driven organization,” says Muth, 48. “[So] I had to figure out … how I was going to move from finance into sales and marketing.”

He arranged a strategic transfer to Ethicon, one of J&J’s more than 150 wholly owned companies — still in finance, but now supporting the sales and marketing group. Then, to demonstrate he was “dead serious,” Muth spent his evenings racking up credits for an MBA in pharmaceutical marketing.

Soon, to his delight, he found himself as a marketing research manager. During the next 15 years Muth launched a handful of market-leading blockbuster drugs, including the antifungal Terazol and popular birth-control pills.

Muth was quickly bumped up to business development as the worldwide director of female healthcare to take advantage of his combination of financial and commercial skills.

By 1996, Muth was geared up for something new. He spent the next five years converting small plasma supplier NaBI of Boca Raton, Fla., into a fully operational biopharmaceutical company.

Now the 90-employee Structural Bioinformatics, based in San Diego, is counting on Muth to do it again: Like so many other bioinformatics tool and data suppliers, SBI now has its sights set on developing drugs. Muth will oversee this transition. He will head the company’s sales and marketing, database production, and R&D operations. “With my commercial background, my commercial experience, I can help the company evolve,” he says.

— Aaron J. Sender

 

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.